Another key from this one - "unexpectedly synergise"....

Another key from this one - "unexpectedly synergise". Wow!

Remember, IIRC, Sud had mentioned in the 2019 AGM that the goal was to really produce a medication that could have a clinically significant (10-15%) AHI reduction compared to baseline, while avoiding the side effects of dronabinol. He also mentioned that the 30% reduction from dronabinol alone was an eye popping moment. Still can't believe we surpassed that to reach over 44% on average.

As others have said, this is a company maker, even if the market does not realise it yet, smart money will very soon. I really regret not topping up today but trying to hold a bit more cash than usual in these times.